Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MR Instruments Inc.

This article was originally published in Start Up

Executive Summary

Higher-field MRI is beginning to arrive in clinical practice, where 3 Tesla systems are often used as a second look, after conventional MRI or other diagnostic methods reveal suspicious findings, for diseases like epilepsy, or to pre-operatively image the extent and location of breast cancer. MR Instruments offers specialized radiofrequency (RF) coils especially suited to high field systems, to improve the signal-to-noise ratio of MR for clearer pictures and to also help researchers obtain other information, like the spectral characteristics of chemicals in the tissue for the study of metabolic processes.

You may also be interested in...



Magnetic Moment

In terms of medical applications magnetic resonance imaging could serve, the modality is still underused, and that means a large, untapped growth opportunity for the entrenched large manufacturers that dominate the industry with an installed base of capital equipment. Small companies have a role to play as well, with adjunctive technologies that serve the large players, or in niches too small for the multi-billion dollar players to notice.

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel